Atrial Fibrillation
Conditions
Keywords
atrial fibrillation, atrial thrombus, cardioversion, enoxaparin, low molecular weight heparin, transesophageal echocardiography
Brief summary
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antithrombotic therapy for patients in atrial fibrillation undergoing transesophageal echocardiography (TEE) guided chemical or electrical cardioversion to sinus rhythm. HYPOTHESIS: Early cardioversion from atrial fibrillation can be safely performed using a short-term anticoagulation strategy of low molecular weight heparin (Lovenox, Sanofi-Aventis) compared to unfractionated heparin, accompanied by a TEE examination prior to cardioversion. The use of LMWH with TEE will result in a safe, cost-effective, and possible efficacious approach to cardioversion of atrial fibrillation compared to UFH with TEE.
Interventions
DRUGEnoxaparin
Sponsors
Sanofi
The Cleveland Clinic
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with chronic or paroxysmal atrial fibrillation of \> 2 days duration who are candidates for early chemical or electrical cardioversion * Patients with atrial flutter with a documented history (electrocardiography) of atrial fibrillation * Males and females 18 years of age or older * Patients have available results of routine clinical labs for standard clinical chemistry and complete blood count within the previous 14 days
Exclusion criteria
* An INR \> 1.4 in patients who have received warfarin prior to enrollment. * Use of IV heparin for more than 72 hours immediately prior to randomization. * Patients with contraindications to TEE, such as dysphagia, or esophageal strictures. * Patients who will need anticoagulation discontinued because of elective intervening procedure, such as cardiac catheterization or surgery. * Patients with contraindications to warfarin or heparin * Patients who require concomitant therapy during the study period with any drug known to affect coagulation or platelet function (i.e. ASA, NSAID, antiplatelet drugs) * Women of childbearing potential, unless pregnancy can be excluded by medical history incompatible with pregnancy or by serum or urine beta HCG levels. * Patients who are hemodynamically unstable and thus may require immediate cardioversion. * Weight less than 40 kg (88 pounds) or more than 125 kg (275 pounds) * History of gastrointestinal bleeding disorder and/or endoscopically verified ulcer disease within the last year * History of intracranial or retinal bleeding, or other known disorders with an increased risk of bleeding * Ischemic stroke in the previous three months * Uncontrolled hypertension (systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 100 mm Hg) * Malignancy currently under active treatment, including melanoma * Patients with renal insufficiency (creatinine \> 2.0 mg/dL) or are renal transplant subjects * Patients with anemia (Hgb less than 10 gm/dL) * Patients with thrombocytopenia (platelet count less than 100 x 10\^9/L) * Positive fecal hemoglobin test * Life expectancy of less than 6 months * History of drug and/or alcohol abuse within the last two years * Patients unable or unwilling to give informed consent * Patients unable or unwilling to return for follow-up * Prisoners or wards of the state * Patients with psychological problems that may decrease compliance with the protocol * Not willing to complete the Quality of Life Questionnaires x 3 * Participating in another clinical trial and/or taking an investigational medication in the past 30 days * Patient language, learning skills, or home environment unconducive to self-management
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| return to normal sinus rhythm (NSR) | — |
| death | — |
| length of stay (LOS) | — |
| ischemic stroke | — |
| transient ischemic attack | — |
| peripheral embolism | — |
| major or minor bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| cost-effectiveness | — |
| quality of life | — |
Countries
United States
Outcome results
None listed